MMP2 and nasopharyngeal carcinoma: Moreover, co-treatment with PSH and ERK1/2 inhibitor (U0126) or JNK1/2 inhibitor (SP600125) contributed to the upregulated activity of MMP-2 in NPC when compared with PSH treatment only group (Figures 4D–G).